MedTrace Logo

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

NCT02742805 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-05-01

No results posted yet for this study

Summary

The proposed research is intended to determine if supplementation of relatively high dose vitamin D in chronic urticaria patients receiving omalizumab will result in continued symptomatic control of hives after the discontinuation of omalizumab.

Conditions

  • Urticaria

Interventions

DIETARY_SUPPLEMENT

Vitamin D (4,000 IU/day)

High Dose of 4,000 IU/day.

DIETARY_SUPPLEMENT

Vitamin D (400 IU/day)

Low Dose of 400 IU/day.

DRUG

Omalizumab

Standard of care dose.

Sponsors & Collaborators

  • Selina Gierer, D.O.

    lead OTHER

Principal Investigators

  • Selina Gierer, D.O. · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742805 on ClinicalTrials.gov